Cost identification analysis for succinylcholine

Franklin Dexter, Tong J. Gan, Mohamed Naguib, David Lubarsky

Research output: Contribution to journalArticle

17 Citations (Scopus)

Abstract

The cost of a dose of succinylcholine from society's perspective equals the acquisition cost of the drug plus the cost of its adverse outcomes. We hypothesized that although the acquisition cost of succinylcholine is minimal, the true cost would be much larger. We reviewed the medical literature to identify the total cost of a dose of succinylcholine when administered for nonemergency purposes according to manufacturers' guidelines (i.e., to adults only). We found that 88% of the cost per dose of succinylcholine was for the chance of dying or sustaining permanent brain injury from anaphylactic or anaphylactoid reactions to succinylcholine. Consequently, the estimated cost per dose of succinylcholine was sensitive to the incidence of anaphylactic or anaphylactoid reactions to succinylcholine, the risk of severe injury from anaphylactic or anaphylactoid reactions, and the financial value of unforeseen instant death or permanent brain injury. The range for the cost per dose of succinylcholine was thus large, $9 to $93. Our best estimate of the cost per dose was $37. We conclude that the true cost per dose of succinylcholine from society's perspective is more than 20 times the acquisition cost. However, a precise costing requires better knowledge of the incidence and consequences of anaphylactic or anaphylactoid reactions to succinylcholine.

Original languageEnglish (US)
Pages (from-to)693-699
Number of pages7
JournalAnesthesia and Analgesia
Volume92
Issue number3
DOIs
StatePublished - Jan 1 2001
Externally publishedYes

Fingerprint

Succinylcholine
Costs and Cost Analysis
Brain Injuries
Drug Costs
Incidence
Guidelines

ASJC Scopus subject areas

  • Anesthesiology and Pain Medicine

Cite this

Cost identification analysis for succinylcholine. / Dexter, Franklin; Gan, Tong J.; Naguib, Mohamed; Lubarsky, David.

In: Anesthesia and Analgesia, Vol. 92, No. 3, 01.01.2001, p. 693-699.

Research output: Contribution to journalArticle

Dexter, Franklin ; Gan, Tong J. ; Naguib, Mohamed ; Lubarsky, David. / Cost identification analysis for succinylcholine. In: Anesthesia and Analgesia. 2001 ; Vol. 92, No. 3. pp. 693-699.
@article{274598db655a408d882d81e4af64d4dc,
title = "Cost identification analysis for succinylcholine",
abstract = "The cost of a dose of succinylcholine from society's perspective equals the acquisition cost of the drug plus the cost of its adverse outcomes. We hypothesized that although the acquisition cost of succinylcholine is minimal, the true cost would be much larger. We reviewed the medical literature to identify the total cost of a dose of succinylcholine when administered for nonemergency purposes according to manufacturers' guidelines (i.e., to adults only). We found that 88{\%} of the cost per dose of succinylcholine was for the chance of dying or sustaining permanent brain injury from anaphylactic or anaphylactoid reactions to succinylcholine. Consequently, the estimated cost per dose of succinylcholine was sensitive to the incidence of anaphylactic or anaphylactoid reactions to succinylcholine, the risk of severe injury from anaphylactic or anaphylactoid reactions, and the financial value of unforeseen instant death or permanent brain injury. The range for the cost per dose of succinylcholine was thus large, $9 to $93. Our best estimate of the cost per dose was $37. We conclude that the true cost per dose of succinylcholine from society's perspective is more than 20 times the acquisition cost. However, a precise costing requires better knowledge of the incidence and consequences of anaphylactic or anaphylactoid reactions to succinylcholine.",
author = "Franklin Dexter and Gan, {Tong J.} and Mohamed Naguib and David Lubarsky",
year = "2001",
month = "1",
day = "1",
doi = "10.1213/00000539-200103000-00028",
language = "English (US)",
volume = "92",
pages = "693--699",
journal = "Anesthesia and Analgesia",
issn = "0003-2999",
publisher = "Lippincott Williams and Wilkins",
number = "3",

}

TY - JOUR

T1 - Cost identification analysis for succinylcholine

AU - Dexter, Franklin

AU - Gan, Tong J.

AU - Naguib, Mohamed

AU - Lubarsky, David

PY - 2001/1/1

Y1 - 2001/1/1

N2 - The cost of a dose of succinylcholine from society's perspective equals the acquisition cost of the drug plus the cost of its adverse outcomes. We hypothesized that although the acquisition cost of succinylcholine is minimal, the true cost would be much larger. We reviewed the medical literature to identify the total cost of a dose of succinylcholine when administered for nonemergency purposes according to manufacturers' guidelines (i.e., to adults only). We found that 88% of the cost per dose of succinylcholine was for the chance of dying or sustaining permanent brain injury from anaphylactic or anaphylactoid reactions to succinylcholine. Consequently, the estimated cost per dose of succinylcholine was sensitive to the incidence of anaphylactic or anaphylactoid reactions to succinylcholine, the risk of severe injury from anaphylactic or anaphylactoid reactions, and the financial value of unforeseen instant death or permanent brain injury. The range for the cost per dose of succinylcholine was thus large, $9 to $93. Our best estimate of the cost per dose was $37. We conclude that the true cost per dose of succinylcholine from society's perspective is more than 20 times the acquisition cost. However, a precise costing requires better knowledge of the incidence and consequences of anaphylactic or anaphylactoid reactions to succinylcholine.

AB - The cost of a dose of succinylcholine from society's perspective equals the acquisition cost of the drug plus the cost of its adverse outcomes. We hypothesized that although the acquisition cost of succinylcholine is minimal, the true cost would be much larger. We reviewed the medical literature to identify the total cost of a dose of succinylcholine when administered for nonemergency purposes according to manufacturers' guidelines (i.e., to adults only). We found that 88% of the cost per dose of succinylcholine was for the chance of dying or sustaining permanent brain injury from anaphylactic or anaphylactoid reactions to succinylcholine. Consequently, the estimated cost per dose of succinylcholine was sensitive to the incidence of anaphylactic or anaphylactoid reactions to succinylcholine, the risk of severe injury from anaphylactic or anaphylactoid reactions, and the financial value of unforeseen instant death or permanent brain injury. The range for the cost per dose of succinylcholine was thus large, $9 to $93. Our best estimate of the cost per dose was $37. We conclude that the true cost per dose of succinylcholine from society's perspective is more than 20 times the acquisition cost. However, a precise costing requires better knowledge of the incidence and consequences of anaphylactic or anaphylactoid reactions to succinylcholine.

UR - http://www.scopus.com/inward/record.url?scp=0035113532&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0035113532&partnerID=8YFLogxK

U2 - 10.1213/00000539-200103000-00028

DO - 10.1213/00000539-200103000-00028

M3 - Article

C2 - 11226104

AN - SCOPUS:0035113532

VL - 92

SP - 693

EP - 699

JO - Anesthesia and Analgesia

JF - Anesthesia and Analgesia

SN - 0003-2999

IS - 3

ER -